Immunoassay Systems | IDS 主营:Immunoassay Systems | IDS试剂盒授权代理商
服务电话: 4009687988
产品目录
联系我们
产品中心
所在位置:

Urine CartiLaps® (CTX-II) EIA

  • 如果您对该产品感兴趣的话,可以
  • 产品名称:Urine CartiLaps® (CTX-II) EIA
  • 产品型号:AC-10F1
  • 产品展商:其它品牌
  • 产品文档:无相关文档
简单介绍

品名:Urine CartiLaps® (CTX-II) EIA 货号:AC-10F1

产品描述
Code: AC-10F1
Certification:

FDA Cleared

Clinical Area: Cartilage Markers
Type: Manual
Format: EIA
RUO/IVD: IVD
Number of Tests: 96 (40 samples in duplicate)
Sample Type: Urine
Sample Volume: 40 µL
Assay Range: 0-10 ng/mL

Unique Features

  • Quantitative assessment of disease activity (structural damage of articular cartilage) in patients with RA and OA
  • Prognosis of disease activity in patients with RA and OA
  • Early assessment of long-term effect of therapy in patients with RA
  • Excellent correlation to immunohistochemistry and imaging techniques
  • A complete assay panel supporting clinical bone and cartilage research

The Urine CartiLaps® (CTX-II) EIA detects degradation products of C-terminal telopeptides of type II collagen.

It is intended for in-vitro diagnostic use as an indication of degradation of cartilage and may be used as an aid for:

  • Quantitative assessment of disease activity (structural damage of articular cartilage) in patients with RA and OA.
  • Prognosis of disease activity in patients with RA and OA, and early assessment of long-term effect of therapy in patients with RA.

Disruption of the structural integrity of cartilage is the major histological finding in osteoarthritis and rheumatoid arthritis. Type II collagen is the major organic constituent of cartilage. Fragments of type II collagen (CTX-II) are being released into circulation and subsequently secreted into urine following degradation of cartilage.

In urine, the CTX-II fragments can be quantified by Urine CartiLaps® (CTX-II) EIA. The Urine CartiLaps® (CTX-II) EIA has been reported to be useful in prediction of the progression of osteoarthritis (Reijman et al.2, Garnero et al1), and in other clinical (Rotterud3) and pre-clinical investigations.

Garnero P. et al., Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort.

Reijman M et al., A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 2004 Aug;50(8):2471-8.

Rotterud JH et al., Relationship between CTX-II and patient characteristics, patient-reported outcome, muscle strength, and rehabilitation in patients with a focal cartilage lesion of the knee: a prospective exploratory cohort study of 48 patients. BMC Musculoskelet Disord. 2014 Mar 24;15:99.

COMP ELISA
Bone Markers


产品留言
标题
联系人
联系电话
内容
验证码
点击换一张
注:1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!